TRPM8 Agonist (Cryosim-1) Cream for Chronic Prurigo: A Randomized, Vehicle-controlled Trial.

Ji Young Um, Han Bi Kim, So Yeon Lee, Bo Young Chung, Chun Wook Park, Hye One Kim

Journal: Acta dermato-venereologica 2025;105():adv44488

PMID: 41261819

Abstract

Chronic prurigo (CP) is a distressing dermatological condition lacking effective topical therapies. This randomized, double-blind, vehicle-controlled trial evaluated the efficacy and safety of Cryosim-1, a TRPM8 agonist cream, in 30 adults with CP. Participants were assigned to apply Cryosim-1 0.1%, 0.5%, or vehicle cream 3 times daily for 4 weeks. Both active formulations significantly reduced Prurigo Activity Score (PAS) compared with vehicle, with 0.1% Cryosim-1 showing a mean PAS reduction of -7.3 (p < 0.001). Significant improvements were observed in 24-h itch intensity, quality of life (DLQI), transepidermal water loss, and stratum corneum hydration. While both concentrations were effective, the 0.1% formulation showed superior tolerability with fewer reports of stinging and erythema. These findings support the potential of TRPM8-targeted therapy in managing CP through dual mechanisms of itch inhibition and skin barrier restoration.

Address: Department of Dermatology, College of Medicine, Hallym University, Kangnam Sacred Heart Hospital, Seoul, Korea.; Department of Dermatology, College of Medicine, Hallym University, Kangnam Sacred Heart Hospital, Seoul, Korea. [email protected].

DOI: 10.2340/actadv.v105.44488

MeSH Terms: Humans, TRPM Cation Channels, Double-Blind Method, Female, Male, Prurigo, Middle Aged, Adult, Treatment Outcome, Chronic Disease, Quality of Life, Administration, Cutaneous, Skin Cream, Antipruritics, Pruritus, Aged, Water Loss, Insensible, Time Factors, Young Adult